Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates

Despite a growing acceptance that withdrawal symptoms can emerge following discontinuation of cannabis products, especially in high-intake chronic users, there are no Food and Drug Administration (FDA)–approved treatment options. Drug development has been hampered by difficulties studying cannabis w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Pharmacol Exp Ther
Autors principals: Kangas, Brian D., Zakarian, Ani S., Vemuri, Kiran, Alapafuja, Shakiru O., Jiang, Shan, Nikas, Spyros P., Makriyannis, Alexandros, Bergman, Jack
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2020
Matèries:
Behavioral Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927407/
https://ncbi.nlm.nih.gov/pubmed/31641018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.261818
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars